Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07605078Recruiting
How Household Mold Affects Your Health
This study looks at whether mold and toxins in your home are connected to physical and mental health problems. Researchers will analyze dust samples you've already tested to understand these links better.
Richmond, VirginiaAges Any age - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Newcastle, New South WalesAges 18 years+ - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT07609823RecruitingPhase 2
Lacutoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia
This trial tests a new drug called lacutoclax (LP-108) in patients whose chronic lymphocytic leukemia or small lymphocytic lymphoma has stopped responding to previous treatments. The drug is designed to work differently than prior therapies and may help patients whose cancer has come back or become resistant to standard care.
Nanjing, JiangsuAges 18 years+ - NCT07609862RecruitingPhase 1/Phase 2
Rocbrutinib and Lacutoclax for B-Cell Blood Cancers
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
TianjinAges 18 years+ - NCT07609719RecruitingPhase 4
Switch to under-the-skin ocrelizumab for multiple sclerosis
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
Scottsdale, ArizonaAges 18–65 - NCT07609940RecruitingPhase 4
Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Los Angeles, CaliforniaAges 18 years+ - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT05767450Recruiting
Test for early type 1 diabetes in children
This study looks at children who have just started insulin for new-onset type 1 diabetes. It aims to test an intervention early in the course of the disease, which may help change how the immune system and diabetes progress.
Milan, MilanAges 7–17 - NCT07604220Recruiting
Exosome Signatures in Cardiac Sarcoidosis Disease Activity
This study looks for disease markers in tiny particles called exosomes in your blood to better understand cardiac sarcoidosis (a condition where inflammation affects the heart). By measuring these markers alongside your standard heart imaging, researchers hope to find better ways to detect and monitor the disease.
Rochester, MinnesotaAges 18 years+ - NCT07610447Recruiting
Virtual Reality vs Treadmill Exercise for Kids With Asthma
This study compares two ways to exercise safely: using virtual reality versus a treadmill. Researchers want to see which method helps children and teens with asthma improve their fitness and breathing.
Istanbul, EyupsultanAges 10–17 - NCT07605806RecruitingPhase 1/Phase 2
Understanding Drug Reactions to Vancomycin
This research study tests a new antibiotic called vancomycin to understand how the body reacts to it and identify early warning signs. If you qualify, you'll help researchers learn more about sudden allergic-like reactions that aren't traditional allergies.
Baltimore, MarylandAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT07611838Recruiting
Predicting ABPA Recurrence Using Blood and Immune Markers
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
Jinan, ShandongAges 18–80 - NCT07606703RecruitingPhase 2
Madecassoside for Hardened Skin After Bone Marrow Transplant
This trial tests whether a plant-derived medicine called madecassoside can help treat sclerotic chronic graft-versus-host disease (a hardening and tightening of the skin that sometimes happens after bone marrow transplant). You would take tablets and be monitored to see if your skin condition improves.
Wuhan, HubeiAges 14–65 - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+ - NCT07606742Recruiting
Exercise Training for Hispanics With Multiple Sclerosis
This study tests a culturally tailored exercise program designed specifically for Hispanic people with multiple sclerosis (MS) who have walking difficulties. The goal is to help improve walking ability and overall quality of life through a personalized exercise plan.
Houston, TexasAges 18 years+ - NCT07604311RecruitingPhase 4
Preventing IgA nephropathy flare-ups with Nefecon
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Guangzhou, GuangdongAges 18–75 - NCT07609134Recruiting
Testing a self-management program for adults with asthma
This study tests a new asthma self-management program designed to help adults better control their asthma in their regular doctor's office. The program teaches practical skills to manage your asthma day-to-day and may help reduce symptoms and improve quality of life.
Dublin, DAges 18 years+ - NCT07604987RecruitingPhase 2
New Treatment for Brain Lymphoma (R-PMDT)
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
TianjinAges 18 years+ - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT07611747RecruitingPhase 4
Ultrasound Screening to Prevent Heart Disease in Rheumatic Patients
This study tests whether using ultrasound to look at arteries in the neck can help prevent heart attacks and strokes in people with inflammatory joint diseases like rheumatoid arthritis or lupus. Researchers will use the results to guide treatment decisions.
Alicante, AlicanteAges 50 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.